Publisher's Note The Review Article by Kunz, entitled, "Carcinoid and Neuroendocrine Tumors: Building on Success" (J Clin Oncol 10.1200/JCO.2014.60.2532), was published online April 27, 2015, with ...

A phase II trial of adjuvant UFT after sequential chemotherapy and radiotherapy in patients with stage IIIB non-small cell lung cancer and non-oriental ethnicity No significant financial relationships ...

Symptoms of neuroendocrine tumors (NETs) can vary depending on their location and severity. General symptoms include extreme fatigue, unexplained weight loss, and loss of appetite. NETs are a rare ...

Patients with neuroendocrine tumors or neuroblastoma could be treated with a different approach based on a protein that may be a potential biomarker. A specific protein could be a potential biomarker ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...

The number of people newly diagnosed with neuroendocrine tumors (NETs) is believed to be increasing, with a higher estimated prevalence than pancreatic or bladder cancer. 5,6,7 Most forms of NETs ...

Dr. Elliott Winford (Medicine): An 86-year-old man was admitted to this hospital because of shortness of breath. The patient had been in his usual state of health until 6 months before the current ...

SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, ...